Clinical trial

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

NCT02775006

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Docetaxel Normalized identity: docetaxelView linked drug · Find medicine records · Find other trials using this name

DRUG · Mapped RxNorm record Erlotinib Normalized identity: erlotinibView linked drug · Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma

Design: INTERVENTIONAL · Status: TERMINATED · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusTERMINATED

Study typeINTERVENTIONAL

Start date2016-10-14

PhasePHASE3

Conditions

Carcinoma, Non-small Cell Lungunresolved

Interventions

DocetaxelDRUG · verified · RxNorm: docetaxel

ErlotinibDRUG · verified · RxNorm: erlotinib

Sponsors & collaborators

The Netherlands Cancer Institutelead sponsor

Dutch Society of Physicians for Pulmonology and Tuberculosiscollaborator

Mapped research locations

RotterdamNetherlands3 GroningenNetherlands1 MaastrichtNetherlands1 UtrechtNetherlands1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT02775006 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.